VERV - Verve Therapeutics, Inc.

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
15.48
+0.15 (+0.98%)
收市:04:00PM EDT
15.94 +0.46 (+2.97%)
收市後: 06:06PM EDT
你目前的瀏覽器並不支援股價圖表
前收市價15.33
開市15.35
買盤0.00 x 1800
賣出價0.00 x 1000
今日波幅15.21 - 16.59
52 週波幅10.70 - 43.00
成交量628,494
平均成交量749,585
市值958.684M
Beta 值 (5 年,每月)
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-3.00
業績公佈日
遠期股息及收益率無 (無)
除息日
1 年預測目標價42.70
  • Insider Monkey

    Top 10 CRISPR Stocks To Buy

    In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy. Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing of specific DNA segments and […]

  • Benzinga

    Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics

    Cantor Fitzgerald initiated coverage on Verve Therapeutics Inc (NASDAQ: VERV) with a Neutral rating and a price target of $21. The analyst says Verve is a true pioneer in gene editing, planning to develop base editing medicines for HeFH and the prevention of ASCVD, both prevalent diseases with large potential markets. However, the analyst sees heightened regulatory and commercial risk compared to other gene-editing/ genetic medicines companies focused on rare diseases. The analyst believes it wo

  • InvestorPlace

    7 CRISPR Stocks With the Best Long-Term Potential

    CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks

  • Insider Monkey

    Cathie Wood Is Loading Up On These 12 Stocks

    In this piece, we will take a look at the top twelve stocks that are on Cathie Wood’s radar. For more stocks, head on over to Cathie Wood Is Loading Up On These 5 Stocks. If there’s one thing that can be said for certain in today’s highly volatile environment, it’s that 2022 has not […]

  • Benzinga

    Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'

    BMO Capital Markets has upgraded Beam Therapeutics Inc (NASDAQ: BEAM) from Market Perform to Outperform and raised the price target from $61 to $66. The analyst writes that it remained on the sidelines due to a lack of near-term stock-moving catalysts. In the most recent earnings release, Beam said it is still working on enrolling its first patient for the trial, dubbed BEACON-101, by year-end. The company announced in its Q3 update that it's pushing back plans to file an IND in 2022 for BEAM-10

  • Insider Monkey

    Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies

    In this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies. GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 […]

  • Insider Monkey

    10 Most Promising Gene Therapy Companies to Watch

    In this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […]

  • Benzinga

    Verve Therapeutics Shares Tumble After FDA Hold On Trial For Elevated Cholesterol Level Candidate

    The FDA has instituted a clinical hold on Verve Therapeutics Inc's (NASDAQ: VERV) IND application to conduct a clinical trial evaluating VERVE-101 in patients with heterozygous familial hypercholesterolemia (HeFH). VERVE-101 is currently being evaluated in the heart-1 Phase 1 clinical trial in New Zealand and the U.K. Verve plans to provide updates pending engagement with the FDA and intends to work closely with the FDA to resolve the hold. Related: Verve's Stock Price Could Continue To Rise Thr

  • Insider Monkey

    Top 10 Stock Picks of Eli Casdin’s Casdin Capital

    In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […]

  • Benzinga

    Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" Competition

    Credit Suisse has initiated coverage on Verve Therapeutics Inc (NASDAQ: VERV) with a Neutral rating and a $48 target price. Its lead assets are VERVE-101 for heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD) and VERVE-201 for homozygous familial hypercholesterolemia (HoFH). The analyst is cautious about VERVE-101, citing a distinct advantage of being a one-time PCSK9 therapy that could free patients from a lifetime of monthly injections. However

  • Benzinga

    Verve Therapeutics Posts Updated Preclinical Data For Gene-Editing Therapy In Cardiovascular Disease

    Verve Therapeutics Inc (NASDAQ: VERV) announced new preclinical data supporting the nomination of the company's second product candidate, VERVE-201. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and triglyceride metabolism. Verve is initially developing VERVE-201 for homozygous familial hypercholesterolemia (HoFH), a rare genetic subtype of atherosclerotic cardiovascular disease (ASCVD) characterized by extremely high blood low-densit

  • Benzinga

    Verve Therapeutics, Vertex Join Forces For Liver Disease-Focused Gene Program

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Verve Therapeutics Inc (NASDAQ: VERV) announced an exclusive, four-year global research collaboration to discover and develop an in vivo gene editing program for undisclosed liver disease. Under the terms of the collaboration, Verve will advance the discovery, research, and certain preclinical development, with all program costs funded by Vertex. Vertex will be responsible for subsequent development, manufacturing, and commercialization of a

  • Insider Monkey

    10 Best Healthcare Stocks To Buy Now According To Motley Fool’s 1623 Capital

    In this article, we talk about the 10 best healthcare stocks to buy now according to Motley Fool’s 1623 Capital. If you wish to skip our detailed analysis of 1623 Capital’s hedge fund performance and stock picks, go directly to 5 Best Healthcare Stocks To Buy Now According To Motley Fool’s 1623 Capital. 1623 Capital […]

  • Benzinga

    Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage

    BMO Capital Markets has raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $61 from $41, with a Market Perform rating unchanged. The model changes include updated collaboration revenues for Verve Therapeutics Inc's (NASDAQ: VERV) VERVE-101 program and the incorporation of the Alpha-1 antitrypsin deficiency (AATD) program, modeled at ~$1 billion peak risk-adjusted sales in 2035E. Related: Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics. BMO says that the key poi

  • Benzinga

    Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics

    Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ: BEAM), which amended the agreement initially announced in April 2019. The original agreement provided Verve with an exclusive, worldwide, sublicensable license under certain of Beam’s base editing, gene editing, and delivery technologies for applications against four liver-mediated cardiovascular disease targets and two undisclosed gene targets. Under